NCT01243424: A reported trial by Boehringer Ingelheim
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01243424 |
|---|---|
| Title | A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Nov. 11, 2010 |
| Completion date | Aug. 21, 2018 |
| Required reporting date | Aug. 21, 2019, midnight |
| Actual reporting date | Aug. 21, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 3, 2025 |
| Days late | None |